I now have comprehensive, current data from CDC 2021 guidelines, multiple textbooks, and recent PubMed papers. Here is the full clinical reference:
Post-Rape STD Prophylaxis and Pregnancy Prevention - Current Clinical Guidelines
Primary source: CDC STI Treatment Guidelines, 2021 (MMWR Vol. 70, No. 4) - current standard of care.
Why Presumptive Treatment?
Follow-up compliance among sexual assault survivors is poor. Because of this, CDC recommends routine presumptive treatment at the initial visit rather than waiting for culture results. An estimated 15% of survivors acquire an STI from the assault. Rates of specific infections after assault:
| STI | Risk (%) |
|---|
| Gonorrhea | 6-18 |
| Chlamydia | 4-17 |
| Trichomonas | ~12 |
| Bacterial vaginosis | ~19 |
| Syphilis | 0.5-3 |
| HIV | <1 |
1. STI Prophylaxis Regimens (CDC 2021)
Standard Regimen (Adults and Adolescents)
Ceftriaxone 500 mg IM in a single dose (for persons ≥150 kg: 1 g)
PLUS
Doxycycline 100 mg orally twice daily for 7 days
PLUS
Metronidazole 500 mg orally twice daily for 7 days
This combination covers:
- Neisseria gonorrhoeae (ceftriaxone)
- Chlamydia trachomatis (doxycycline)
- Trichomonas vaginalis and bacterial vaginosis (metronidazole)
- Incubating syphilis (ceftriaxone)
Note on doxycycline: A negative pregnancy test is required before prescribing doxycycline or tetracycline (contraindicated in pregnancy). In pregnant patients, use erythromycin as an alternative for chlamydia coverage. Metronidazole can cause nausea and vomiting - stagger administration by a few hours if given alongside emergency contraception to avoid vomiting affecting EC efficacy.
Alternative for Chlamydia (if doxycycline unavailable)
Azithromycin 1 g orally in a single dose (though doxycycline is now preferred due to lower resistance rates)
If Ceftriaxone Unavailable
Cefixime 400 mg orally in a single dose (for gonorrhea coverage only)
2. HIV Post-Exposure Prophylaxis (HIV-PEP)
Key Principles
- Must be started as soon as possible, within 72 hours of exposure
- Course: 28 days
- PEP has NO benefit if started >72 hours post-exposure
- Based on extrapolation from occupational needlestick data (81% risk reduction with 28-day ZDV course)
- Risk of HIV from sexual assault is heightened vs. consensual sex due to tissue trauma/mucosal disruption
Risk Assessment Before Offering PEP
- Is the assailant known HIV-positive?
- Is the assailant in a high-risk group (IDU, MSM, sex worker)?
- What orifice was penetrated (rectal >> vaginal for HIV risk)?
- Was there visible trauma/bleeding?
If the assailant's HIV status is unknown, offer PEP with individualized counseling on risks and benefits.
Recommended HIV PEP Regimen (from CDC/DHHS nPEP Guidelines)
Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) 300/200 mg once daily
PLUS
Raltegravir 400 mg twice daily (or dolutegravir 50 mg once daily)
Duration: 28 days
Practical Logistics
- Provide an initial 3-7 day starter pack at the first visit, with a prescription for the full 28-day course
- Providing the entire 28-day supply at the initial visit improves adherence, especially when follow-up is uncertain
- Refer to: National Clinicians' Consultation Center PEP Hotline: 1-888-448-4911
- Uninsured patients: enroll in manufacturer patient-assistance programs
After PEP Completion
- Survivors who took HIV PEP should be evaluated for HIV PrEP after completing the course and testing HIV-negative
3. Hepatitis B Prophylaxis
For unvaccinated survivors:
- Hepatitis B vaccine at time of examination (first dose), with follow-up doses at 1-2 months and 4-6 months
- Give as soon as possible (within 24 hours ideally)
When assailant is known HBsAg-positive and survivor is non-immune:
- Hepatitis B Immune Globulin (HBIg) + vaccine simultaneously at separate sites
- HBIg is NOT recommended if first presentation is ≥14 days after assault
For previously vaccinated survivors:
- Test hepatitis B surface antibody; re-vaccinate if negative
4. HPV Vaccination
- Recommended for all survivors aged 9-26 years (some guidelines extend to age 45)
- Initiate at the first visit; complete the series at follow-up
- Note: HPV vaccines do NOT provide therapeutic benefit to existing infections, but protect against future exposures
5. Pregnancy Prevention (Emergency Contraception)
First Priority: Rule Out Existing Pregnancy
- Urine or serum beta-hCG before administering EC
- ECPs are ineffective (but not harmful) if the woman is already pregnant
Emergency Contraception Options (in order of efficacy)
| Method | Timing | Efficacy | Notes |
|---|
| Copper IUD (Cu-IUD) | ≤5 days post-assault | ~99% | Most effective; also provides ongoing contraception. Caution: do NOT insert if patient has untreated gonorrhea, chlamydia, or purulent cervicitis (Category 4) |
| Ulipristal acetate (UPA) | ≤5 days (120 hrs) | ~85% | Prescription required; may be more effective than LNG at 72-120 hrs |
| Levonorgestrel (LNG) | ≤3 days (72 hrs); some efficacy to 5 days | ~75-89% | OTC; start ASAP |
| Combined estrogen/progestin pill (Yuzpe method) | ≤72 hrs | ~57-75% | More side effects; rarely used now |
CDC U.S. MEC classification for sexual assault: Category 2 for most ECPs (benefits outweigh risks), noting that routine presumptive treatment for chlamydia, gonorrhea, and trichomoniasis should also be initiated. Cu-IUD is Category 1 unless concurrent STI.
Note on Metronidazole + EC
Nausea and vomiting from metronidazole can reduce absorption of oral EC. Stagger the doses by several hours if administering both at the same visit.
6. STI Testing at Initial Examination (Selective)
Routine STI cultures are NOT recommended at the initial visit unless the survivor is symptomatic or is a child. Recommended initial testing includes:
- NAAT for C. trachomatis and N. gonorrhoeae (vaginal/cervical/rectal/pharyngeal as appropriate)
- Serum: HIV, hepatitis B (HBsAg, HBsAb), syphilis (RPR/VDRL)
- Wet prep or NAAT for T. vaginalis
- Urine or serum beta-hCG (pregnancy test)
- Consider toxicology (urine/blood) if drug-facilitated assault suspected
7. Follow-Up Schedule
| Timepoint | Action |
|---|
| <1 week (early) | Discuss initial test results, assess PEP adherence/side effects, adjust regimen if needed, provide any vaccines not given initially |
| 1-2 weeks | Repeat STI testing if initial tests negative and treatment not given |
| 1-2 months | Second hepatitis B vaccine (if initiated), repeat HIV test, RPR for syphilis |
| 4-6 months | Third hepatitis B vaccine, final HIV test, RPR repeat |
8. Recent Evidence Updates (2023-2025)
[Review . 2025] Dutra K, Lewis AL, Counts R. "Sexually Transmitted Infection Considerations Following Sexual Assault." Clin Obstet Gynecol. Confirms that 15% of survivors acquire an STI; prophylaxis recommended for gonorrhea, chlamydia, and (in those with vaginas) trichomonas; HIV and Hep B PEP indicated in high-risk scenarios; HPV vaccination recommended. [PMID: 39962703]
[Review . 2024] Kane D, Holmes A, Eogan M. "Post-exposure prophylaxis, STI testing and factors associated with follow-up attendance: review of 4159 cases." Sex Transm Infect. In practice, EC was given to 53.8%, chlamydia PEP to 75.1%, HIV PEP to 11.0%, and Hep B vaccination to 53.7% of acute presentations. Factors predicting follow-up: adolescent age, concern about drug-facilitated assault, absence of recreational drug use. [PMID: 37977653]
[Review . 2023] Yesodharan R et al. "The role of legal medicine professionals in preventing pregnancy and STIs among female victims of sexual assault." Forensic Sci Med Pathol. Emphasizes prompt evaluation is critical as delay adversely affects EC and PEP efficacy. [PMID: 36881378] [PMC: PMC10518277]
[CDC 2024] CDC Clinical Guidelines on Doxycycline Post-Exposure Prophylaxis (Doxy-PEP) - Doxycycline 200 mg taken within 72 hrs after condomless sex reduces chlamydia by ~70% and syphilis by ~73% in MSM/transgender women; no significant effect on gonorrhea. Evidence base for routine doxy-PEP in sexual assault populations is still limited.
Quick Reference Summary Card
POST-RAPE PROPHYLAXIS CHECKLIST
□ Pregnancy test (beta-hCG)
□ EC - LNG (≤72h) / UPA (≤120h) / Cu-IUD (≤5 days, most effective)
STI PROPHYLAXIS
□ Ceftriaxone 500 mg IM stat (1 g if ≥150 kg)
□ Doxycycline 100 mg PO BD × 7 days (if not pregnant)
□ Metronidazole 500 mg PO BD × 7 days
HIV PEP (if indicated - within 72 hours)
□ TDF/FTC + raltegravir or dolutegravir × 28 days
□ Hotline: 1-888-448-4911
VACCINATIONS
□ Hepatitis B vaccine (dose 1) if unvaccinated
□ HPV vaccine (ages 9-26) if not completed
□ HBIg if assailant known HBsAg+ and survivor non-immune
FOLLOW-UP
□ <1 week: PEP check, test results
□ 1-2 months: Hep B dose 2, HIV retest
□ 4-6 months: Hep B dose 3, final HIV test
Sources: CDC STI Treatment Guidelines 2021; Roberts & Hedges' Clinical Procedures in Emergency Medicine; Berek & Novak's Gynecology; Rosen's Emergency Medicine; PMID 39962703, 37977653, 36881378